View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsGlobal Bioenergies 과거 순이익 실적과거 기준 점검 0/6Global Bioenergies은 연평균 12.1%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 연평균 4.4%의 비율로 감소했습니다. 매출은 연평균 45.6%의 비율로 증가했습니다.핵심 정보12.06%순이익 성장률28.86%주당순이익(EPS) 성장률Chemicals 산업 성장률12.41%매출 성장률45.65%자기자본이익률-346.31%순이익률-1,625.06%최근 순이익 업데이트31 Dec 2024최근 과거 실적 업데이트Reported Earnings • Mar 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €8.91m (up €8.33m from FY 2022). Net loss: €8.66m (loss narrowed 28% from FY 2022). Revenue is expected to decline by 53% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.6%.Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €1.72m (up 106% from FY 2021). Net loss: €12.0m (loss widened 1.8% from FY 2021). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in Germany.Reported Earnings • Oct 03First half 2021 earnings released: €0.69 loss per share (vs €0.80 loss in 1H 2020)First half 2021 results: Net loss: €7.62m (loss widened 9.9% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 26Full year 2020 earnings released: €1.10 loss per share (vs €1.65 loss in FY 2019)Full year 2020 results: Net loss: €11.1m (loss narrowed 23% from FY 2019). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.28m (up €3.16m from FY 2019). Net loss: €11.1m (loss narrowed 13% from FY 2019).Reported Earnings • Sep 21First half earnings releasedOver the last 12 months the company has reported total losses of €12.1m, with losses narrowing by 2.5% from the prior year.모든 업데이트 보기Recent updatesBoard Change • Nov 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Oct 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Mar 22Global Bioenergies SA, Annual General Meeting, May 15, 2025Global Bioenergies SA, Annual General Meeting, May 15, 2025. Location: 5 rue henri desbrueres, evry courcouronnes FranceBoard Change • Jan 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Nov 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • Oct 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.84m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$580k). Market cap is less than US$10m (€8.84m market cap, or US$9.58m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).New Risk • Oct 10New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€146k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$585k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (€24.0m market cap, or US$26.2m).Board Change • Aug 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Jun 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • May 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 4.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€33.2m market cap, or US$36.1m).공시 • May 12Global Bioenergies SA, Annual General Meeting, Jun 27, 2024Global Bioenergies SA, Annual General Meeting, Jun 27, 2024. Location: 5 rue henri desbrueres, evry courcouronnes FranceNew Risk • Apr 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 6.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Market cap is less than US$100m (€36.9m market cap, or US$39.3m).Board Change • Apr 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Mar 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €8.91m (up €8.33m from FY 2022). Net loss: €8.66m (loss narrowed 28% from FY 2022). Revenue is expected to decline by 53% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.6%.Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Oct 19Global Bioenergies Announces the Appointment of Martin Stephan as Chief Business OfficerGlobal Bioenergies announced Martin Stephan joins the company as chief business officer. Martin Stephan has spent his entire career in the chemical industry, in France, Germany, Italy and Switzerland. As Deputy Chief Executive Officer of CARBIOS from 2017 to 2022, he notably contributed to the strong growth of this major listed player in the green chemistry market. He previously held strategic positions as Head of International Sales in global groups, particularly in The Chemours Company and Du Pont de Nemours, the world leader in innovative specialty products for industry. Martin Stephan is a graduate of HEC.Board Change • Oct 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Breakeven Date Change • Mar 31No longer forecast to breakevenThe analyst covering Global Bioenergies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €4.70m in 2025. New forecast suggests the company will make a loss of €1.30m in 2025.Breakeven Date Change • Feb 21Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 31% per year to 2024. The company is expected to make a profit of €4.70m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €1.72m (up 106% from FY 2021). Net loss: €12.0m (loss widened 1.8% from FY 2021). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in Germany.Breakeven Date Change • Feb 14Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests the company will make a profit of €4.70m in 2025. Average annual earnings growth of 39% is required to achieve expected profit on schedule.공시 • Sep 23Global Bioenergies SA Completes REWOFUEL ProjectGlobal Bioenergies SA announced the end of the REWOFUEL project, which ran from 1 June 2018 to 30 June 2022. This project brought together several European industries such as Repsol, Sekab and Fibenol, with the objective of demonstrating the conversion of wood residues into sustainable high-performance components for road and aviation fuels,and thus participate to the decarbonization efforts of ground and air transportation. The project was coordinated by Global Bioenergies and received €13.8 million in funding from the European Horizon 2020 research and innovation programme. For this project, sugars from wood were supplied by Sekab and Fibenol. These sugars were then processed into high performance sustainable biofuels. As a result, batches of bio-isooctane, bio-ETBE and sustainable aviation fuel have been produced by Global Bioenergies and then tested by Repsol, Spain’s leading oil company. Batches of sustainable aviation fuel were produced and transferred to SkyNRG, leader in the sustainable aviation fuel industry. Significant work has been coordinated by SkyNRG for the certification of these isobutene derivatives as a sustainable aviation fuel. Meanwhile, by-products from the ligneous part of wood chips have been incorporated by Peab into successfully implemented bitumen products. Producing bitumen with a better environmental footprint will help to optimise overall road transport performance. The proteins resulting from fermentation are intended to be used in animal feed. The experiments conducted by Metex NoovistaGo in this respect have produced positive results. Finally, the Energie Institut JKU has carried out life cycle analyses of the various segments of this value chain and has quantified the reduction in CO2 emissions according to different configurations, which can lead to savings of up to 85% compared to the benchmark fossil solution. Meanwhile, engineering efforts have been conducted by Neste, Technip-FMC, and IPSB, a French engineering company specialized in agribusinesses.Breakeven Date Change • Mar 06Forecast to breakeven in 2024The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 20% per year to 2023. The company is expected to make a profit of €700.0k in 2024. Average annual earnings growth of 56% is required to achieve expected profit on schedule.공시 • Feb 10Global Bioenergies Announces New Molecule for the Greening of C5 ChemistryGlobal Bioenergies has developed a process for converting plant resources into isobutene, one of the main building blocks of chemistry, whose derivatives are used in cosmetics, fine chemicals, commodities and fuels. A production unit is currently under construction in Pomacle to serve high value-added markets. One of the intermediates in the isobutene synthesis pathway is of industrial interest: this 5-carbon intermediate, prenic acid, is also known as “methyl-crotonic acid”, “dimethyl-acrylic acid” and “senecic acid” (CAS 541-47-9). Its two chemical functions (acid and vinyl) allow it to be used in a multitude of compounds that are currently derived from petroleum and used most notably in flavours, perfumes and food additives. A non-exhaustive overview of the prenic acid product tree is available on the Technology page of the Global Bioenergies website: it illustrates the range of products and domains accessible from this molecule.Breakeven Date Change • Feb 01Forecast to breakeven in 2024The 2 analysts covering Global Bioenergies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €700.0k in 2024. Average annual earnings growth of 48% is required to achieve expected profit on schedule.Reported Earnings • Oct 03First half 2021 earnings released: €0.69 loss per share (vs €0.80 loss in 1H 2020)First half 2021 results: Net loss: €7.62m (loss widened 9.9% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.공시 • Sep 15Global Bioenergies Launches Lip Make-Up Range for Its Last Cosmetics BrandGlobal Bioenergies announced the launch of a lip make-up range for its LAST brand, in addition to the existing eye make-up offer. Like the 18 mascara, eyebrow mascara and liquid eyeshadow products on the market since June, the 14 liquid lipsticks are a combination of high performance and high naturalness. This combination is only possible Global Bioenergies innovative product: naturally sourced isododecane.공시 • Jul 02Global Bioenergies Releases Second Commercial Batch of Naturally Sourced IsododecaneGlobal Bioenergies SA has finished producing and released its second batch of naturally sourced isododecane. Besides fuelling the Company’s own brand, LAST, this batch will also be used to distribute product samples to the many cosmetic industry players who have requested it. Six months after releasing its first batch of naturally sourced isododecane, Global Bioenergies has finished producing and released a second batch of the innovative ingredient to be marketed from 2022 under the name of Isonaturane 12. The second batch of naturally sourced isododecane is also used to serve the numerous cosmetic industry players who have requested sampling.공시 • Jun 15Global Bioenergies Launches of LAST brandGlobal Bioenergies launches its LAST brand, the first range of longwear make-up with over 90% natural ingredients: the range’s 18 mascara, eyebrow mascara and eye shadow products can now be obtained. Instrumental tests and clinical studies demonstrate performance on a par with the best conventional products on the market: this is the first time a brand with over 90% natural ingredients has delivered such a performance. Independent laboratories conducted numerous instrumental tests and clinical tolerance and use studies on the products. The performance of the range was compared to leading products on the market in terms of hold, water resistance, level of transfer, sensory qualities and pleasure of application. The results demonstrate 24-hour hold, waterproofness and low-transfer property for each of the product categories. Tests conducted over a long period (21 days) under dermatological and ophthalmological supervision validated tolerance to use. The products’ sensory qualities were also highly appreciated: for example, after blind testing, 85% of women said they would like to continue using LAST eye shadow and would recommend it to their friends, considering that, independently of naturalness, the product is equivalent to or better than their usual eye shadow.Breakeven Date Change • May 19No longer forecast to breakevenThe 2 analysts covering Global Bioenergies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.20m in 2023. New consensus forecast suggests the company will make a loss of €7.65m in 2023.공시 • May 05Global Bioenergies Announces the Upcoming Launch of “LAST®” Longwear CosmeticsGlobal Bioenergies announced the upcoming launch of its “LAST®” longwear cosmetics brand in June 2021. This groundbreaking performance is based on the renewable isododecane produced by the Company as the main ingredient of its formulations. Products have been designed with over 90% natural ingredients and packaging to minimise their environmental footprint. Prototypes were refined and went into industrial production at one of Europe’s leading make-up manufacturers. Packaging made from mineral (glass or metal), biosourced or recycled materials was specified, designed and prototyped. The LAST® brand currently has three categories of product: mascaras, eyebrow mascaras and eye shadows, all lasting at least 24 hours. Allowing for the different colours, the full range has 18 products, now in production in a French plant.Reported Earnings • Apr 26Full year 2020 earnings released: €1.10 loss per share (vs €1.65 loss in FY 2019)Full year 2020 results: Net loss: €11.1m (loss narrowed 23% from FY 2019). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.28m (up €3.16m from FY 2019). Net loss: €11.1m (loss narrowed 13% from FY 2019).Is New 90 Day High Low • Jan 15New 90-day high: €9.26The company is up 194% from its price of €3.15 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.Is New 90 Day High Low • Nov 25New 90-day high: €3.90The company is up 11% from its price of €3.51 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period.Reported Earnings • Sep 21First half earnings releasedOver the last 12 months the company has reported total losses of €12.1m, with losses narrowing by 2.5% from the prior year.매출 및 비용 세부 내역Global Bioenergies가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BST:1DK 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 240-68030 Sep 243-77030 Jun 240-710031 Mar 242-810031 Dec 233-911030 Sep 232-912030 Jun 234-1013031 Mar 232-1114031 Dec 221-1214030 Sep 221-1113030 Jun 221-1013031 Mar 221-1113031 Dec 211-1214030 Sep 210-1216030 Jun 210-1214031 Mar 210-1114031 Dec 200-1113030 Sep 200-1313030 Jun 200-1213031 Mar 200-1213031 Dec 190-1413030 Sep 191-1310030 Jun 191-1213031 Mar 191-1313031 Dec 181-1414030 Sep 181-1615030 Jun 180-1716031 Mar 180-1615031 Dec 170-1414030 Sep 170-1113030 Jun 171-1013031 Mar 171-1013031 Dec 161-1114030 Sep 160-1116030 Jun 161-1112031 Mar 161-1112031 Dec 151-1012030 Sep 151-911030 Jun 151-810031 Mar 152-710031 Dec 142-690양질의 수익: 1DK 은(는) 현재 수익성이 없습니다.이익 마진 증가: 1DK는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 1DK는 수익성이 없지만 지난 5년 동안 연평균 12.1%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 1DK의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 1DK은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(-13.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 1DK는 현재 수익성이 없으므로 자본 수익률이 음수(-346.31%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/05 06:37종가2025/12/01 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Global Bioenergies SA는 6명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Markus MayerBaader Helvea Equity ResearchMark CartlichEdison Investment ResearchAlexandre LetzGilbert Dupont3명의 분석가 더 보기
Reported Earnings • Mar 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €8.91m (up €8.33m from FY 2022). Net loss: €8.66m (loss narrowed 28% from FY 2022). Revenue is expected to decline by 53% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.6%.
Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €1.72m (up 106% from FY 2021). Net loss: €12.0m (loss widened 1.8% from FY 2021). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Oct 03First half 2021 earnings released: €0.69 loss per share (vs €0.80 loss in 1H 2020)First half 2021 results: Net loss: €7.62m (loss widened 9.9% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 26Full year 2020 earnings released: €1.10 loss per share (vs €1.65 loss in FY 2019)Full year 2020 results: Net loss: €11.1m (loss narrowed 23% from FY 2019). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.28m (up €3.16m from FY 2019). Net loss: €11.1m (loss narrowed 13% from FY 2019).
Reported Earnings • Sep 21First half earnings releasedOver the last 12 months the company has reported total losses of €12.1m, with losses narrowing by 2.5% from the prior year.
Board Change • Nov 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Oct 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Mar 22Global Bioenergies SA, Annual General Meeting, May 15, 2025Global Bioenergies SA, Annual General Meeting, May 15, 2025. Location: 5 rue henri desbrueres, evry courcouronnes France
Board Change • Jan 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Nov 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • Oct 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.84m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$580k). Market cap is less than US$10m (€8.84m market cap, or US$9.58m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).
New Risk • Oct 10New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€146k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$585k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (€24.0m market cap, or US$26.2m).
Board Change • Aug 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jun 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • May 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 4.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€33.2m market cap, or US$36.1m).
공시 • May 12Global Bioenergies SA, Annual General Meeting, Jun 27, 2024Global Bioenergies SA, Annual General Meeting, Jun 27, 2024. Location: 5 rue henri desbrueres, evry courcouronnes France
New Risk • Apr 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 6.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Market cap is less than US$100m (€36.9m market cap, or US$39.3m).
Board Change • Apr 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Mar 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €8.91m (up €8.33m from FY 2022). Net loss: €8.66m (loss narrowed 28% from FY 2022). Revenue is expected to decline by 53% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.6%.
Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Oct 19Global Bioenergies Announces the Appointment of Martin Stephan as Chief Business OfficerGlobal Bioenergies announced Martin Stephan joins the company as chief business officer. Martin Stephan has spent his entire career in the chemical industry, in France, Germany, Italy and Switzerland. As Deputy Chief Executive Officer of CARBIOS from 2017 to 2022, he notably contributed to the strong growth of this major listed player in the green chemistry market. He previously held strategic positions as Head of International Sales in global groups, particularly in The Chemours Company and Du Pont de Nemours, the world leader in innovative specialty products for industry. Martin Stephan is a graduate of HEC.
Board Change • Oct 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Breakeven Date Change • Mar 31No longer forecast to breakevenThe analyst covering Global Bioenergies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €4.70m in 2025. New forecast suggests the company will make a loss of €1.30m in 2025.
Breakeven Date Change • Feb 21Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 31% per year to 2024. The company is expected to make a profit of €4.70m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €1.72m (up 106% from FY 2021). Net loss: €12.0m (loss widened 1.8% from FY 2021). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in Germany.
Breakeven Date Change • Feb 14Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests the company will make a profit of €4.70m in 2025. Average annual earnings growth of 39% is required to achieve expected profit on schedule.
공시 • Sep 23Global Bioenergies SA Completes REWOFUEL ProjectGlobal Bioenergies SA announced the end of the REWOFUEL project, which ran from 1 June 2018 to 30 June 2022. This project brought together several European industries such as Repsol, Sekab and Fibenol, with the objective of demonstrating the conversion of wood residues into sustainable high-performance components for road and aviation fuels,and thus participate to the decarbonization efforts of ground and air transportation. The project was coordinated by Global Bioenergies and received €13.8 million in funding from the European Horizon 2020 research and innovation programme. For this project, sugars from wood were supplied by Sekab and Fibenol. These sugars were then processed into high performance sustainable biofuels. As a result, batches of bio-isooctane, bio-ETBE and sustainable aviation fuel have been produced by Global Bioenergies and then tested by Repsol, Spain’s leading oil company. Batches of sustainable aviation fuel were produced and transferred to SkyNRG, leader in the sustainable aviation fuel industry. Significant work has been coordinated by SkyNRG for the certification of these isobutene derivatives as a sustainable aviation fuel. Meanwhile, by-products from the ligneous part of wood chips have been incorporated by Peab into successfully implemented bitumen products. Producing bitumen with a better environmental footprint will help to optimise overall road transport performance. The proteins resulting from fermentation are intended to be used in animal feed. The experiments conducted by Metex NoovistaGo in this respect have produced positive results. Finally, the Energie Institut JKU has carried out life cycle analyses of the various segments of this value chain and has quantified the reduction in CO2 emissions according to different configurations, which can lead to savings of up to 85% compared to the benchmark fossil solution. Meanwhile, engineering efforts have been conducted by Neste, Technip-FMC, and IPSB, a French engineering company specialized in agribusinesses.
Breakeven Date Change • Mar 06Forecast to breakeven in 2024The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 20% per year to 2023. The company is expected to make a profit of €700.0k in 2024. Average annual earnings growth of 56% is required to achieve expected profit on schedule.
공시 • Feb 10Global Bioenergies Announces New Molecule for the Greening of C5 ChemistryGlobal Bioenergies has developed a process for converting plant resources into isobutene, one of the main building blocks of chemistry, whose derivatives are used in cosmetics, fine chemicals, commodities and fuels. A production unit is currently under construction in Pomacle to serve high value-added markets. One of the intermediates in the isobutene synthesis pathway is of industrial interest: this 5-carbon intermediate, prenic acid, is also known as “methyl-crotonic acid”, “dimethyl-acrylic acid” and “senecic acid” (CAS 541-47-9). Its two chemical functions (acid and vinyl) allow it to be used in a multitude of compounds that are currently derived from petroleum and used most notably in flavours, perfumes and food additives. A non-exhaustive overview of the prenic acid product tree is available on the Technology page of the Global Bioenergies website: it illustrates the range of products and domains accessible from this molecule.
Breakeven Date Change • Feb 01Forecast to breakeven in 2024The 2 analysts covering Global Bioenergies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €700.0k in 2024. Average annual earnings growth of 48% is required to achieve expected profit on schedule.
Reported Earnings • Oct 03First half 2021 earnings released: €0.69 loss per share (vs €0.80 loss in 1H 2020)First half 2021 results: Net loss: €7.62m (loss widened 9.9% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
공시 • Sep 15Global Bioenergies Launches Lip Make-Up Range for Its Last Cosmetics BrandGlobal Bioenergies announced the launch of a lip make-up range for its LAST brand, in addition to the existing eye make-up offer. Like the 18 mascara, eyebrow mascara and liquid eyeshadow products on the market since June, the 14 liquid lipsticks are a combination of high performance and high naturalness. This combination is only possible Global Bioenergies innovative product: naturally sourced isododecane.
공시 • Jul 02Global Bioenergies Releases Second Commercial Batch of Naturally Sourced IsododecaneGlobal Bioenergies SA has finished producing and released its second batch of naturally sourced isododecane. Besides fuelling the Company’s own brand, LAST, this batch will also be used to distribute product samples to the many cosmetic industry players who have requested it. Six months after releasing its first batch of naturally sourced isododecane, Global Bioenergies has finished producing and released a second batch of the innovative ingredient to be marketed from 2022 under the name of Isonaturane 12. The second batch of naturally sourced isododecane is also used to serve the numerous cosmetic industry players who have requested sampling.
공시 • Jun 15Global Bioenergies Launches of LAST brandGlobal Bioenergies launches its LAST brand, the first range of longwear make-up with over 90% natural ingredients: the range’s 18 mascara, eyebrow mascara and eye shadow products can now be obtained. Instrumental tests and clinical studies demonstrate performance on a par with the best conventional products on the market: this is the first time a brand with over 90% natural ingredients has delivered such a performance. Independent laboratories conducted numerous instrumental tests and clinical tolerance and use studies on the products. The performance of the range was compared to leading products on the market in terms of hold, water resistance, level of transfer, sensory qualities and pleasure of application. The results demonstrate 24-hour hold, waterproofness and low-transfer property for each of the product categories. Tests conducted over a long period (21 days) under dermatological and ophthalmological supervision validated tolerance to use. The products’ sensory qualities were also highly appreciated: for example, after blind testing, 85% of women said they would like to continue using LAST eye shadow and would recommend it to their friends, considering that, independently of naturalness, the product is equivalent to or better than their usual eye shadow.
Breakeven Date Change • May 19No longer forecast to breakevenThe 2 analysts covering Global Bioenergies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.20m in 2023. New consensus forecast suggests the company will make a loss of €7.65m in 2023.
공시 • May 05Global Bioenergies Announces the Upcoming Launch of “LAST®” Longwear CosmeticsGlobal Bioenergies announced the upcoming launch of its “LAST®” longwear cosmetics brand in June 2021. This groundbreaking performance is based on the renewable isododecane produced by the Company as the main ingredient of its formulations. Products have been designed with over 90% natural ingredients and packaging to minimise their environmental footprint. Prototypes were refined and went into industrial production at one of Europe’s leading make-up manufacturers. Packaging made from mineral (glass or metal), biosourced or recycled materials was specified, designed and prototyped. The LAST® brand currently has three categories of product: mascaras, eyebrow mascaras and eye shadows, all lasting at least 24 hours. Allowing for the different colours, the full range has 18 products, now in production in a French plant.
Reported Earnings • Apr 26Full year 2020 earnings released: €1.10 loss per share (vs €1.65 loss in FY 2019)Full year 2020 results: Net loss: €11.1m (loss narrowed 23% from FY 2019). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.28m (up €3.16m from FY 2019). Net loss: €11.1m (loss narrowed 13% from FY 2019).
Is New 90 Day High Low • Jan 15New 90-day high: €9.26The company is up 194% from its price of €3.15 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.
Is New 90 Day High Low • Nov 25New 90-day high: €3.90The company is up 11% from its price of €3.51 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period.
Reported Earnings • Sep 21First half earnings releasedOver the last 12 months the company has reported total losses of €12.1m, with losses narrowing by 2.5% from the prior year.